anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the last decades hospitalization rates of patients with acute pyelonephritis (AP) or FUTI has decreased from almost 100% to 10-30%. The outpatient management of patients with FUTI has become popular as well as oral antimicrobial treatment regiments and shortening of treatment duration. However, as such approaches are only discovered in otherwise young health non-pregnant women, the best management of FUTI in the elderly, men and patients with co-morbidity remains elusive. Bases on personal perception of the attending physician antibiotic treatment, duration varies approximately between 7-14 days. Facing the aging of the general population, it is urgent to better define the optimal treatment for AP or FUTI in an unselected population and to identify those at risk for treatment failure or poor outcome to guide and optimize individual patient management and to prevent on the one hand unnecessary long treatment duration and hospital admission and on the other hand unsafe short duration or unsafe outpatient management.

In this study the efficacy and safety of a 7-day antimicrobial regimen compared to a 14-day antimicrobial regimen will be evaluated in an unselected population presenting with FUTI at primary care or emergency department. In addition a clinical and/or biomarker based scoring system of disease severity will be derived to predict those at risk for treatment failure or poor outcome.
A class of three substances has been isolated in highly purified form and in substantially pure form by utilizing thymus tissue as a source material. These three substances are designated thymone A, thymone B and thymone C. Thymones A and B are new peptides which yield approximately 13 and 14 individual amino acid moieties, respectively, on acid hydrolysis. Thymones A and B are chemically characterized by electrophoretic and chromatographic values which are appropriate for substances which are substantially pure. Thymone C was highly purified and its biological activity was reproducibly detected and measured. Thymones A, B and C stimulate the proliferation of lymphocytes. Thymone A stimulates the formation of cyclic adenosine monophosphate. Thymone B stimulates the formation of cyclic guanosine monophosphate. The biological activities of these thymones to stimulate the proliferation of lymphocytes and the formations of cyclic nucleotides are basic hormonal functions for the therapeutic enhancement of the immune system in patients who have immune deficiencies from diverse causes.
PURPOSE:To obtain an oil gel cosmetic capable of improving the feeling of use without impairing the stability. CONSTITUTION:This oil get cosmetic comprises (A) 0.05-20wt.% hydrophobic aerosol silica. gel obtained by hydrolyzing silicon tetrachloride in an oxyhydrogen flame and subjecting the resultant hydrophilic aerosol silica gel to the hydrophobizing treatment, (B) 5-40wt.% wax, e.g. microcrystalline wax or ceresin and (C) 20-90wt.% liquid fats and oils, e.g. liquid paraffin or dimethylpolysiloxane. The introducing treatment of trimethylsiloxy group with trimethylsilyl chloride or hexamethyldisilazane, methylating treatment with dimethyldichlorodisilane, coating and baking treatment with hydrogenmethylpolysiloxane, coating with a metallic soap, etc., are cited as a method for hydrophobizing treatment in the ingredient (A).
The invention is applicable to the technical field of genetic engineering, and provides a nano antibody specifically binding hepatitis E virus capsid protein and application thereof, wherein the nucleotide sequences of the nano antibody are respectively shown as SEQ ID NO. 1 and SEQ ID NO. 2, and the amino acid sequences of the nano antibody are respectively shown as SEQ ID NO. 3 and SEQ ID NO. 4. The nano antibody specifically binding to the hepatitis E virus capsid protein can specifically bind to human, pig and rabbit HEV 239 proteins, is expressed and purified by utilizing a prokaryotic expression system, and is respectively incubated with the pig HEV 239 protein or the pig HEV and then inoculated with HpG2 cells, so that the antiviral function is exerted.
BACKGROUND: Total energy expenditure (TEE) is the total energy expended by an individual to sustain life, activities, and growth. TEE is formed by four components: resting energy expenditure (REE), activity energy expenditure (AEE), growth-related energy expenditure (GEE), and the thermic effect of feeding (TEF). Some energy expenditure (EE) components may change throughout childhood and cannot be reliably estimated using prediction formulae.
OBJECTIVE: To summarize measured TEE components as reported in the literature in healthy and critically ill children.
METHODS: We searched MEDLINE, EMBASE, and CINAHL for studies published between 1946 and 7 September 2023. The primary outcome was energy expenditure. Included studies were published in English and measured one or more of TEE, AEE, GEE, and TEF with Indirect Calorimetry or Doubly Labeled Water in participants between 1 month and 18 years of age. We excluded studies reporting only REE or using predictive equations. Following abstraction, reported values were converted into kcal/kg/day or kcal/day as possible. Weighted mean values were calculated using median or means of EE measurements.
RESULTS: We found 138 studies, 8163 patients, and 16,636 eligible measurements. The median (IQR) study sample size was 20 (12, 35) patients. TEE was the most evaluated component. The median (IQR) TEE in infants was 73.1 (67.0, 76.5), in children 78.0 (66.0, 81.3), and in adolescents was 44.2 (41.8, 51.9) kcal/kg/day. Very few studies reported on GEE and TEF.
CONCLUSIONS: This is one of the first studies that summarizes components of total energy expenditure in different pediatric age groups in healthy and critically ill children. Growth- and feeding-associated energy expenditure are poorly reported in healthy children, while all components of TEE (except REE) are poorly reported in critically ill children.
Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
Within the framework of Taabo HDSS Cross-sectional community and health services surveys are performed before wound management intervention (main study and substudy 1) is implemented (baseline) and are continued at 6 monthly intervals thereafter. Surveys are done door-to-door. All patients with skin lesions (broken skin barrier) are enrolled, lesions are documented with help of a questionnaire and photographic documentation.
Large volume leukapheresis (LVL) is increasingly used to collect peripheral blood stem cells (PBSCs) and other mononuclear cells (MNC) for hematopoietic and immune reconstitution, with recent emphasis on increased processing volumes. Decreases in divalent cation levels caused by administration of citrate anticoagulant during LVL can be associated with severe donor reactions, and may limit the rate at which blood can be processed. Several donors at NIH experienced citrate-related hypocalcemic tetany during LVL, in response to which we developed standard operating procedures for the routine administration of prophylactic intravenous calcium solutions during longer apheresis procedures. Other centers have utilized heparin to reduce the amount of citrate returned to the donor, however, this exposes the donor to systemic anticoagulation and may be associated with hematomas or clumping of the apheresis product.

We previously determined that citrate administration during apheresis results in significant excretion of calcium and magnesium in the urine during the procedure, and that performance of prolonged or repeated LVL causes significant depletion of blood calcium and magnesium levels. Decreases in calcium levels were ameliorated during procedures performed with prophylactic calcium administration. Our preliminary studies also demonstrated that ionized magnesium levels were markedly reduced during LVL as well as plateletpheresis procedures. The clinical impact of severe, acute decreases in ionized magnesium levels in healthy apheresis donors is not clear, however. Since most of the adverse effects related to citrate administration can be prevented by prophylactic calcium administration, it is unknown what aspect of the remaining discomfort may be attributable to hypomagnesemia. This protocol will focus on determining the contribution of acute hypomagnesemia to citrate-related symptoms during large-volume apheresis, and establishing the role of and indications for prophylactic intravenous magnesium replacement in this setting. The study plan will consist of a prospective, randomized, placebo-controlled, double-blind study. Healthy allogeneic donors will be assigned to one of two treatment groups. One group will receive intravenous magnesium infusions throughout scheduled LVL procedures; the other group will receive equivalent volume infusions of normal saline. Symptoms and blood samples will be obtained by apheresis nurses and laboratory assays will be performed by associate laboratory investigators, all in a blinded fashion.
Infants born \< 32 weeks, in an incubator, and \> 7 days postnatal that were maintained on either on NCPAP or HFNC to maintain SaO2 in a range of 88 - 92 %. Study infants had decibel measurements obtained every 15 seconds for 30 minutes using a noise dosimeter (NoisePro DLX-1). The microphone for the dosimeter was suspended from the inside of the incubator such that it hung 1 foot above the infants nose and mouth. The exhalation port for NCPAP was placed outside of the incubator. Repeated measurement periods on the same mode of support were made within a 72 hour period. Each infant the acted as their own control and was switched within 7 days to the alternative respiratory support method that maintained similar SaO2 goals and repeat measurements were obtained. Comparisons of mean decibel levels during recording were compared using paired t-tests.
The present invention generally relates to inhibitors of DUOX1. In some aspects, an inhibitor may be applied to a subject having or being at risk for asthma or other conditions. The inhibitor may be applied by various techniques, such as pulmonary or topical delivery. In some embodiments, the inhibitor may include a peptide or other moiety having a reactive electrophile. The reactive electrophile can target cysteine or other residues within DUOX1 to inhibit its activity, e.g., by covalently binding to the residue. Other non-limiting examples of suitable inhibitors include hydroxynonenal, curcumin, sulforaphane, cinnamaldehyde, dimethyl fumarate, or phenyl vinyl sulfonate. Other aspects of the invention are generally directed to methods of making or using such inhibitors, kits involving such inhibitors, devices or formulations containing such inhibitors, or the like.
PROBLEM TO BE SOLVED: To obtain a novel compound which is useful for obtaining a benzoic acid derivative comprising a specific bicyclic amide compound, having retinoid activity and useful as medicines. SOLUTION: This benzoic acid derivative is a compound expressed by formula I (R1 is a lower alkyl or an aryl; R2 and R7 are each H or a lower alkyl; R3 to R6 are each a lower alkyl), e.g. 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6- acetaminonaphthalene. The compound of formula I is obtained by carrying out the Friedel-Crafts reaction using 1 mole of an acylated aniline derivative of formula II with preferably 1.5-2 mole of 1,4-dihalobutane derivative of formula III (X is a halogen) and preferably 1.5-2 mole of a Lewis acid (e.g. AlCl3, etc.), a protonic acid (e.g. sulfuric acid, etc.), etc., as a catalyst. As a solvent, a halogenated hydrocarbon is preferably used. It is preferable to carry out the reaction at temperatures ranging from a room temperature to a cooled temperature for 0.5-20 hours.
A composition for treating and preventing obesity comprising the extract of Zizyphus jujuba Mill. var. inermis Rehder is provided to inhibit body weight increase, reduce neutral lipid concentration and cholesterol concentration, and increase high density cholesterol concentration. The composition for treating and preventing obesity comprises the extract of Zizyphus jujuba Mill. var. inermis Rehder as an effective ingredient, wherein the Zizyphus jujuba Mill. var. inermis Rehder extract is prepared with a solvent selected from water, ethanol and methanol; the amount of the Zizyphus jujuba Mill. var. inermis Rehder extract is 0.1-50 wt.%; the daily dosage of Zizyphus jujuba Mill. var. inermis Rehder extract is 0.0001 to 100 mg/kg; and the composition is a health food composition.
The patients receive LESP block for postoperative pain management at the beginning of the surgery. The LESP block will be provided with 40 ml 0,25% bupivacaine under ultrasonography. Following the block performance, patients received spinal anesthesia at the L3-L4 level with 20 mg heavy bupivacaine. All patients will receive the same postoperative multimodal analgesia regimen, which includes intravenous paracetamol 1000 mg every 6 hours and intramuscular diclofenac 75 mg every 12 hours. In addition, intravenous patient-controlled analgesia (PCA) with morphine will be administered for 48 hours postoperatively, with a bolus dose of 1 mg and a lockout interval of 10 minutes (no basal rate). If the Numeric Rating Scale (NRS) exceeds 4, intravenous tramadol (1.5 mg/kg) will be administered as rescue analgesia.
Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
PCT No. PCT/US97/20981 Sec. 371 Date May 20, 1999 Sec. 102(e) Date May 20, 1999 PCT Filed Nov. 13, 1997 PCT Pub. No. WO99/25388 PCT Pub. Date May 27, 1999N-demethylated and N,N-demethylated derivatives of toluidine blue O and compositions which include these derivatives and the conformational isomers of toluidine blue O. Improved methods for the detection of dysplastic oral tissue using such compositions. Processes for synthesis of toluidine blue O products, in which a complexing agent is introduced prior to the last stage of oxidation of a three-step synthesis from N,N-dimethyl- rho -phenylenediamine. An HPLC method for characterizing toluidine blue O products in which the mobile phase is an aqueous solution of an organic acid.
Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
The invention relates to a human brain tissue specific gene LRRC4 monoclonal antibody, its preparation and an application method. According to the invention, a peptide with good hydrophilicity, high antigen index and high sequence specificity is selected from a LRRC4 full-length protein as animal immunogen. Polymerase chain reaction is applied to clone a nucleotide sequence for coding the peptide. A His fusion expression vector containing the nucleotide sequence is constructed. Then the expression of the His fusion protein is induced. Balb/c mouse is immunized with the purified protein. Spleen cells and myeloma cells SP2/0 of the mouse are separated for fusion. By positive clone screening and subcloning, fusion cells are used for ascites preparation and purification to obtain an anti-LRRC4 monoclonal antibody. The expression of LRRC4 is specifically high in normal human brain tissue and is down-regulated in glioma. The preparation of the anti-LRRC4 monoclonal antibody will provide a useful tool for in-depth study of LRRC4 biological function so as to provide a novel idea and method for the diagnosis and treatment of glioma.
Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
Veterans living with lower-limb amputation have poor physical health outcomes, multiple chronic comorbidities, high medical service utilization, and high levels of disability. Self-reported disability for people living with lower limb amputation is greater than 95% of the general population. One way to reduce disability for Veterans with lower-limb amputation is for them to participate in life-long sustained walking exercise. Regular exercise improves functional independence and mental well-being, and reduces adverse effects of common comorbidities associated with lower-limb amputation, such as diabetes and peripheral artery disease. However, most Veterans with lower-limb amputation do not regularly exercise. Only 50% of people with lower limb amputation achieve levels of walking activity that support participation in their local community, creating a critical need to improve physical exercise participation after lower-limb amputation. Evidence suggests that clinician-supported exercise in a person's home living environment that includes evidence-based promotion of patient self-management has promise for interrupting the cycle of elevated sedentary behavior and poor health outcomes. Therefore, the primary aim of this randomized controlled superiority trial is to determine if a telerehabilitation walking exercise self-management program produces clinically meaningful walking exercise sustainability compared to attention-control education. This novel, low-cost intervention includes a novel combination of piloted behavior-change methods and clinical resources, including VA multidisciplinary telehealth sessions, individual exercise self-management training, and VA peer-group sessions. In addition, the intervention is integrated within an established VA Regional Amputation Center, using established VA clinical telerehabilitation and technology. Exercise and physical activity will be monitored as a continuous daily outcome, with secondary outcomes assessed at a baseline test and then after 6 and 18 months of intervention participation. The primary outcome will be accelerometer-assessed daily walking step count monitored continuously each day across the 18-month study period. Secondary outcomes are designed to assess the potential to assess how to best translate the walking exercise intervention into conventional VA amputation rehabilitation. These secondary outcomes include measures of intervention reach, intervention efficacy, likelihood of clinical adoption, potential for clinical implementation, and ability of participants to maintain long-term exercise behavior. The unique rehabilitation paradigm used in this study addresses the problem of chronic sedentary lifestyles following lower-limb amputation with a home-based exercise model of life-long exercise support from clinicians and peers. The trial results will advance rehabilitation knowledge and provide the necessary evidence for larger clinical translation of self-management intervention to sustain walking exercise for Veterans living with lower-limb amputation.
Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
The invention discloses a fish-killing Edwardsiella phage, a phage composition and application thereof, wherein the phage is named PRE03, and is preserved in China general microbiological culture Collection center on the year 2022, on the day 07 of 01, the preservation address is No. 3 of the Xilu No. 1 of Beijing Korean district, and the preservation number is CGMCC No. 45074. The invention also provides a phage composition comprising the Edwardsiella piscicida phage PRE03 as described above. The bacteriophage not only has strong infection capacity and cracking capacity, but also has high thermal stability and acid-base stability, is a bacteriophage capable of efficiently killing Edwardsiella multocida, and has safe use and wide application range; the bacteriophage and the bacteriophage composition thereof can be effectively used for preventing and treating infection caused by killing the Edwardsiella ichthyophthirii, and can be widely used for various links easily causing loss caused by killing the Edwardsiella ichthyophii due to infection in the aquaculture process, daily disinfection of the aquaculture environment, bacteriostasis of aquatic fresh food and the like.
Heart failure (HF) with reduced ejection fraction (HFrEF) is a risk factor for drug-induced QT interval prolongation. It is unknown if HF with preserved ejection fraction (HFpEF) is also associated with an increased risk. Dofetilide and sotalol are potent QT interval-prolonging agents that are frequently used in patients with HFpEF, in whom atrial fibrillation is a common comorbidity. We tested the hypothesis that the risk of QT interval prolongation associated with dofetilide and sotalol is increased in patients with HFpEF. We conducted a retrospective cohort study conducted using electronic health records from the Indiana Network for Patient Care (January 31, 2010 -May 3, 2021). After removing patients with overlapping diagnoses of HFpEF and HFrEF, no diagnosis code, and absence of QT interval records, we identified patients taking dofetilide or sotalol among three groups: HFrEF (n = 138), HFpEF (n = 109), and no HF (n = 729). QT prolongation was defined as heart rate-corrected QT (QTc) > 500 ms during dofetilide/sotalol therapy. Unadjusted odds ratios (OR) for QT prolongation were determined by univariate analysis. Adjusted ORs were determined by generalized estimating equations (GEE) with logit link to account for an individual cluster with different times of hospitalization and covariates. QTc prolongation associated with dofetilide or sotalol occurred in 53.2%, 71.7% and 30.0% of patients with HFpEF, HFrEF, and patients with no HF, respectively. After adjusting for age, sex, race, serum potassium and magnesium concentrations, kidney function, concomitant drug therapy, and comorbid conditions, the adjusted odds of QTc prolongation were significantly higher in patients with HFpEF [OR = 1.98 (95% CI 1.17-3.33)], and in those with HFrEF [OR = 5.23, (3.15-8.67)], compared to those with no evidence of HF. The odds of QT prolongation among inpatients receiving dofetilide or sotalol were increased in patients with HFpEF and HFrEF compared to those who did not have HF.
The invention discloses a medical image fine-granularity classification method based on segmentation large model guidance, and belongs to the technical field of medical images. Firstly, generating a coarse mask through a segmentation network to serve as a prompt of a SAM, carrying out fine processing on the coarse mask to obtain a fine mask, and then generating a frame prompt by using the fine mask and a maximum connected graph. The SAM may receive various types of input cues, such as points, boxes, etc., that may help the model more accurately identify and segment objects in the image. And segmenting and analyzing the image by using the SAM to generate a segmented mask image. And inputting the segmented mask into PaNet classification network to classify the image in fine granularity. The invention is superior to the traditional medical image fine granularity classification method in the aspects of object positioning and segmentation, generalization capability, partial discovery performance, classification precision and the like, so that the invention has wide application prospect in the medical image analysis field.